Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mecasermin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Details : Under the licensing agfreement, Esteve will hold the rights of Increlex (mecasermin). It is being indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency.
Product Name : Increlex
Product Type : Hormone
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Mecasermin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.
Product Name : E-58425
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
